Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Diagnostic marker-C16orf74 gene of renal clear cell carcinoma

A technology of renal clear cell carcinoma and gene, applied in the field of biomedicine, can solve the problems of less than 10% 5-year survival rate, complex pathogenesis and limited curative effect, etc.

Active Publication Date: 2018-09-14
THE FIRST AFFILIATED HOSPITAL OF ARMY MEDICAL UNIV
View PDF1 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Like other types of RCC, cc-RCC is not sensitive to radiotherapy, chemotherapy and hormone therapy, and the effect of immunotherapy is not satisfactory. In recent years, some progress has been made in biological targeted therapy for advanced renal cancer, but the curative effect is still very limited
Surgical resection is still the main treatment at present, and the 5-year survival rate of small, well-differentiated early cc-RCC without metastasis can reach 90%; but once metastasis occurs, the 5-year survival rate is less than 10%
Current research shows that the occurrence and development of renal cell carcinoma is a multi-factor, multi-gene abnormality and multi-stage process, and the pathogenesis is extremely complex

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Diagnostic marker-C16orf74 gene of renal clear cell carcinoma

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0061] Example 1 Screening of Differentially Expressed Genes in Renal Clear Cell Carcinoma Tissue

[0062] 1. Sample collection

[0063] All 5 cases were ccRCC patients admitted to the Department of Urology of the hospital. The 3 cancer tissue specimens were all frozen in liquid nitrogen tanks 0.5 hours after radical nephrectomy for future use, and the 2 normal kidney tissue specimens were taken from the normal area of ​​T1 renal carcinoma more than 5cm away from the primary tumor. All specimens were confirmed by routine pathological examination, and rechecked by the hospital pathology department before the experiment. All experimental specimens were collected with the consent of the patients or their family members.

[0064] 2. Extraction of total RNA from samples

[0065]About 50-100 mg of the above tissue samples were taken, and Trizol was added to extract total RNA, and the concentration and purity of the samples were measured with a Beckman DU530 ultraviolet spectropho...

Embodiment 2

[0075] Example 2 Verification of Differentially Expressed Genes in Large Samples

[0076] The C16orf74 gene, which was suggested to be differentially expressed between clear cell renal cell carcinoma tissue and normal kidney tissue by high-throughput sequencing, was selected as the research target for large-scale validation.

[0077] 1. Tissue acquisition and processing: 45 cases of renal clear cell carcinoma tissues and 45 cases of normal renal tissues were collected according to the method in Example 1.

[0078] 2. RNA extraction

[0079] RNA extraction was carried out according to the method of Example 1.

[0080] 3. cDNA synthesis by reverse transcription

[0081] Take 2 μg of total RNA, add 5 μl T7 promoter primer, add nuclease-free water to a total reaction volume of 11.5 μl, bathe in water at 65°C for 10 minutes, place on ice for 5 minutes, then add 8.5 μl cDNA Master Mix (containing 5x first strand Buffer 4μl, 0.1mol / L DTT 2mol / L. 10mol / L dNTP mixture 1μl, reverse t...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a C16orf74 gene which can be taken as a biomarker for the renal clear cell carcinoma. The experiment proves that compared with normal nephridial tissues, the C16orf74 gene expression in renal clear cell carcinoma tissues is significantly improved. According to the research result, the C16orf74 gene can be applied to research and development of a kit used for diagnosing therenal clear cell carcinoma and also can be used for researching and developing medicines capable of inhibiting the C16orf74 gene expression, thereby achieving clinical prevention and treatment for therenal clear cell carcinoma.

Description

technical field [0001] The invention belongs to the field of biomedicine and relates to a diagnostic marker for renal clear cell carcinoma, in particular to the application of C16orf74 gene in the diagnosis of renal clear cell carcinoma. Background technique [0002] Renal cell carcinoma (RCC), also known as renal cell carcinoma, renal adenocarcinoma, adrenal adenoid tumor, etc., is the most common renal parenchymal malignant tumor, accounting for 3% of human malignant tumors in the whole body, and its incidence rate ranks first among urinary system malignant tumors. the second place. The incidence of RCC is increasing year by year in European and American countries. According to statistics, there are about 30,000 new RCC patients in the United States every year, and about 12,000 people die of RCC-related diseases every year. The male to female ratio of kidney cancer incidence is about 3.5:1, often occurs after the age of 40, occasionally under the age of 30. Renal carcino...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C12Q1/6886G01N33/574A61K45/00A61P35/00
CPCA61K45/00A61P35/00C12Q1/6886C12Q2600/158G01N33/57438G01N33/57484G01N2333/47
Inventor 周强申兵冰刘宏赵洪雯于艳杰梅玫徐小松
Owner THE FIRST AFFILIATED HOSPITAL OF ARMY MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com